Achieving clinically meaningful and approvable endpoints in glaucoma neuroprotection is challenging today 8 Glaucoma clinical endpoints Currently studied Prevention of nerve fiber layer thinning (via RGC loss) No Visual field ( mean ≥ 7dB in an area consisting of at least 5 points) No IOP reduction Yes • Nerve fiber loss and visual field are the two clinically meaningful endpoints in glaucoma neuroprotection • No therapy has demonstrated preservation • Bar for clinical trials to show this level of superiority is very high